Pilin Biosciences: The amount of investment in 2025 is expected to increase by over 20% compared to the previous year.

Pailin Biologicals stated on the Shenzhen Stock Exchange interactive platform that the company currently has obtained approvals from over 10 county-level authorities and over 5 city-level authorities. In 2025, the company will focus on expanding new plasma stations and strive to achieve a breakthrough in new plasma stations. In addition, the company mentioned that the year-on-year decline in operating performance in the first quarter of 2025 was mainly due to the suspension of production capacity expansion at its subsidiary, Pisfe Co. Phase II, but after the capacity expansion, the expected plasma input in 2025 will exceed 1400 tons, with a year-on-year growth of over 20%. The company's profit growth target rate will be maintained at double digits.